Exclusive Online Content
Sever Pharma Solutions Acquires Foster Delivery Science
Sever Pharma Solutions (SPS) recently announced it has entered into a definitive agreement to acquire the assets of Foster Delivery Science (FDS) located in Putnam, CT…..
Arranta Bio Announces Completion of Sale of Florida Site & Progress on $150-Million Investment Plan to Expand Development & Commercial Manufacturing Services
Arranta Bio recently announced the completion of the sale of its process development and GMP clinical manufacturing site in Gainesville, FL, to Inceptor Bio and the transfer of client programs and key….
SOTIO Expands Its Antibody-Drug Conjugate Pipeline With Exclusive Collaboration & License Agreement With LegoChem Biosciences
SOTIO Biotech recently announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc in which SOTIO will obtain rights to deploy LCB’s ADC technology for up to….
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline With a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) & Other Rare Ocular Surface Diseases
Kala Pharmaceuticals, Inc. recently announced it has acquired Combangio, Inc., a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases…..
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform
Harpoon Therapeutics, Inc. recently presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, DC…..
Baxter Announced $100-Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
Baxter International Inc. recently announced an approximately $100-million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. This facility is….
Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy With Curative Potential for RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. recently announced that the company has executed an exclusive license agreement with Leiden University Medical Centre (LUMC) for a first-in-class ex vivo lentiviral gene therapy for the….
First Own Gerresheimer Autoinjector - Gerresheimer & Midas Pharma Announce Strategic Partnership
Gerresheimer recently announced it has acquired the IP of a new generation cartridge-based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector…
PDC* line Pharma Opens Last Cohort of PDC-Lung-101 Clinical Trial
PDC*line Pharma recently announced the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 Phase 1/2 clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer….
ESCP Models - Hepatitis C Medications (Part 2), Oral Therapeutics
Part 2 of this series fills in the story starting with the first oral HCV therapeutic, Vertex’s Incivek (telaprevir), which predated the first of the Gilead therapeutics by 2.5 years…
EXCLUSIVE ONLINE CONTENT
Biolojic Design Announces Nektar Therapeutics Has Exercised its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021….
Cellares & Bristol Myers Squibb Announce $380-M Worldwide Capacity Reservation & Supply Agreement
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across its IDMO Smart Factories in the US, EU, and Japan for Bristol Myers Squibb’s use ….
Neurolentech Signs Technology Access Partnership With Kaerus Bioscience
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes….
Palisade Bio Enters Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach
Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers….
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….